Lobe Sciences Ltd.
LOBE
CNSX
11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
---|---|---|---|---|---|
Revenue | -- | -100.00% | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -100.00% | -- | -- | -- |
Cost of Revenue | -- | -37.78% | -- | -- | -- |
Gross Profit | -- | -101.83% | -- | -- | -- |
SG&A Expenses | 34.46% | -57.81% | -42.98% | -21.09% | -26.99% |
Depreciation & Amortization | -- | -100.00% | 61.72% | 5,150.00% | 2,200.00% |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | -7.33% | -79.66% | 63.90% | -40.33% | -26.21% |
Operating Income | -15.58% | 64.06% | -63.90% | 40.33% | 40.84% |
Income Before Tax | -39.90% | -132.52% | -36.17% | 40.33% | 72.20% |
Income Tax Expenses | -- | -84.33% | -- | -- | -- |
Earnings from Continuing Operations | -39.90% | -100.21% | -36.17% | 40.33% | 72.20% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -39.90% | -100.21% | -36.17% | 40.33% | 72.20% |
EBIT | -15.58% | 64.06% | -63.90% | 40.33% | 40.84% |
EBITDA | -17.80% | 63.24% | -64.02% | 43.18% | 43.79% |
EPS Basic | 35.85% | -86.15% | 0.00% | 42.27% | 75.00% |
Normalized Basic EPS | 36.36% | 54.55% | -18.75% | 41.67% | 49.23% |
EPS Diluted | 35.85% | -86.15% | 0.00% | 42.27% | 75.00% |
Normalized Diluted EPS | 36.36% | 54.55% | -18.75% | 41.67% | 49.23% |
Average Basic Shares Outstanding | 119.50% | 7.85% | 38.92% | 2.99% | 12.13% |
Average Diluted Shares Outstanding | 119.50% | 7.85% | 38.92% | 2.99% | 12.13% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |